Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108688 | 0.74 | ALDH1A1 (0.45) | THRB | |
| SCHEMBL4113095 | 0.74 | BPTF (0.37) | THRB | |
| SCHEMBL11264823 | 0.63 | GABRA1 (0.50) | THRB | |
| SCHEMBL29915097 | 0.62 | GPR35 (0.36) | — | |
| SCHEMBL27002510 | 0.62 | GPR35 (0.36) | — | |
| SCHEMBL3800127 | 0.61 | MAPT (0.45) | THRB | |
| SCHEMBL3986078 | 0.61 | LMNA (0.43) | THRB | |
| SCHEMBL4354925 | 0.60 | THRB (0.55) | THRB | |
| SCHEMBL14609815 | 0.60 | LMNA (0.39) | — | |
| SCHEMBL31035737 | 0.60 | GABRA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | REPLIDYNE, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | REPLIDYNE, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | REPLIDYNE, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | REPLIDYNE, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | REPLIDYNE, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | REPLIDYNE, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054667-A1 | Transition metal catalyzed cross-coupling of 1-halo-1-haloalkene compounds | TDO2, TALDO1, NAT1 | THRB 2821/4885 |
| US-20080194842-A1 | Transition Metal Catalyzed Cross-Coupling Of 1-Halo-1-Haloalkene Compounds | TDO2, TALDO1, NAT1 | THRB 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.